AI in Clinical Trials in 2026: Patient Recruitment, Site Selection, and Operations
Clinical trials AI has substantial deployment. Where it sits in 2026.
AI in clinical trials has substantial production deployment across major operational categories. By 2026 the patterns are clearer and substantial CRO/sponsor deployments are mature. This post walks through what’s actually shipping.
The production use cases#
Several substantial categories:
Patient recruitment. AI identifies candidate patients from EHR data; substantial improvement over traditional outreach. Substantial reduction in recruitment time.
Site selection. ML models predict site enrollment performance based on substantial historical data; substantial improvement in site selection decisions.
Protocol optimization. Substantial protocol design augmented by AI evaluation of feasibility and enrollment likelihood.
Real-time data monitoring. Substantial central monitoring with AI-augmented anomaly detection. Substantial replacement of substantial monitoring visits.
Decentralized trial support. Substantial AI for substantial wearable data analysis, substantial telemedicine integration, substantial substantial home-based assessments.
Substantial document automation. Substantial regulatory documents generated and reviewed by AI.
Substantial substantial pharmacovigilance. Substantial AE detection from substantial EHR and substantial patient-reported data.
The vendor landscape#
Substantial categories:
Clinical trial platforms with AI:
- Veeva Vault EDC + AI features.
- Medidata Rave + AI.
- Oracle Clinical with AI augmentation.
Specialized AI:
- Deep 6 AI — patient identification.
- Inato — site selection.
- TrialSpark, Reify Health — substantial newer trial platforms.
- Owkin — substantial federated learning for clinical research.
EHR integration vendors:
- IQVIA, ICON with substantial data lake offerings.
The substantial regulatory dimension#
Substantial considerations:
FDA guidance on AI in clinical research — substantial evolving framework.
EMA approach — substantial cautious adoption.
GxP requirements — substantial AI in regulated environments requires substantial validation.
Substantial data quality — substantial real-world data quality matters substantially for AI training.
What we typically see#
Common patterns:
AI-augmented recruitment — most common production use.
Decentralized trial substantial AI integration — substantial growing.
Substantial monitoring AI at substantial sophisticated trial operations.
Substantial early adoption at substantial larger pharma and CROs; substantial slower at smaller operators.
Where pdpspectra fits#
Our data engineering practice supports pharma and CRO operations with clinical data platforms and AI integration.
Related reading: the AI banking production post, the AI clinical voice documentation post, and the GDPR AI systems post.
Clinical trials AI is substantial production-mature. Talk to our team about your clinical AI platform.